Sinopharm Holdings is a new drug developed by the voice, which has been listed in the national medical insurance catalogue of China. Therefore, it can be considered that Zhi Nuo is a new medical insurance drug.
However, it should be noted that whether the medical insurance expenses can be reimbursed depends on the specific policies and regulations in the region. Some areas may only reimburse some drugs, or the proportion of drug reimbursement is limited. Therefore, if you need to use Zenoxin and want to be reimbursed through medical insurance, I suggest you consult the local medical insurance policy or relevant departments first to ensure that you can get satisfactory reimbursement. Sinuoxin is a drug which is packaged by Zhi Nuo Wei tablets and ritonavir tablets. Mainly used for treating adult patients with mild to moderate novel coronavirus infection. Sentenovir tablets can inhibit the activity of COVID-19 3CL protease, thus blocking virus replication, while ritonavir tablets can help slow down the metabolism or decomposition of Sentenovir tablets, thus increasing its plasma concentration and enhancing its antiviral effect.
When using sanoxin, patients should take it as soon as possible within 3 days after symptoms appear, take it orally on an empty stomach and swallow it whole. It is not allowed to chew, break or crush it. The recommended dose is 0.750 g tenofovir (2 tablets) combined with 0. 1 g ritonavir (1 tablet) once every 12 hours, which usually takes effect in about 2 days. It is recommended to take it continuously for 5 days.
It should be noted that if patients suffer from other chronic diseases, heavy smoking, overweight or obesity and other high-risk factors, it is necessary to closely observe the curative effect when using Linuoxin and use it as soon as possible to obtain the best effect. In addition, if the patient is allergic during use, he should stop taking the medicine immediately and seek the help of a doctor.
In terms of safety, SANOXIN showed good safety and tolerability in clinical trials, and most of the adverse reactions were mild to moderate, which could be alleviated after drug withdrawal. However, due to the limited sample size of clinical trials, it cannot be completely ruled out that some patients may have serious adverse reactions. Therefore, patients still need to pay attention to their physical condition, and seek medical attention in time if they have abnormal reactions.
In a word, China Xinbao is a drug for adult patients infected by novel coronavirus, which can inhibit virus replication and improve antiviral effect. When using, patients should use it correctly according to the doctor's instructions or instructions, and pay attention to their physical condition. If there is any abnormal reaction, you should seek medical advice in time.
To sum up: As a new drug, Zhi Nuo has been listed in China's national medical insurance catalogue, so it can be considered as a medical insurance drug. However, the specific reimbursement situation needs to be determined according to the medical insurance policy in the region.
Legal basis:
Article 28 of the Social Insurance Law of People's Republic of China (PRC) stipulates: "Medical expenses that meet the basic medical insurance drug list, diagnosis and treatment items, medical service facilities standards and emergency rescue shall be paid by the basic medical insurance fund in accordance with state regulations."